Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.53B | 1.57B | 1.91B | 2.25B | 2.17B | 1.85B |
Gross Profit | 375.52M | 406.39M | 506.06M | 602.14M | 560.32M | 440.64M |
EBITDA | -12.76M | -3.54M | 11.46M | 115.61M | 96.00M | -126.04M |
Net Income | -33.85M | -125.75M | -14.17M | 62.27M | 61.63M | -141.84M |
Balance Sheet | ||||||
Total Assets | 672.78M | 675.38M | 899.38M | 1.02B | 1.03B | 980.58M |
Cash, Cash Equivalents and Short-Term Investments | 21.90M | 22.54M | 61.88M | 72.05M | 49.90M | 62.51M |
Total Debt | 110.10M | 66.53M | 61.34M | 62.56M | 67.02M | 68.73M |
Total Liabilities | 367.59M | 360.02M | 441.51M | 523.09M | 540.16M | 543.39M |
Stockholders Equity | 305.19M | 315.36M | 457.87M | 496.31M | 493.07M | 437.19M |
Cash Flow | ||||||
Free Cash Flow | -54.71M | -41.21M | 3.48M | 89.88M | -14.57M | 125.47M |
Operating Cash Flow | -34.91M | -17.06M | 34.75M | 120.50M | 20.44M | 152.53M |
Investing Cash Flow | -16.93M | -2.45M | -32.32M | -20.95M | -16.22M | -34.41M |
Financing Cash Flow | 48.55M | -17.09M | -37.58M | -64.69M | -19.13M | -92.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $10.80B | 16.55 | 6.58% | 2.06% | 2.37% | -15.86% | |
58 Neutral | $140.72M | 57.86 | 4.06% | 2.60% | -9.76% | -53.41% | |
56 Neutral | $89.38M | 109.45 | 1.01% | ― | 5.16% | ― | |
51 Neutral | $497.40M | 11.43 | -0.49% | 2.06% | 0.97% | -112.75% | |
49 Neutral | $112.34M | 268.89 | -8.83% | ― | -8.31% | -445.30% | |
48 Neutral | $178.21M | ― | -10.53% | ― | -13.01% | 68.18% | |
48 Neutral | $66.62M | ― | -9.13% | 4.69% | -24.36% | -393.95% |
TrueBlue reported its second quarter 2025 financial results, showing a revenue of $396 million, which remained flat compared to the previous year. The company achieved a net loss of $0 million, a significant improvement from the $105 million net loss in the prior year, attributed to non-cash impairment and tax valuation charges. TrueBlue’s strategic focus on skilled trades, healthcare, and energy markets, along with investments in proprietary technologies, is expected to drive future growth and enhance operational efficiency. The company is optimistic about returning to growth in the third quarter, with a focus on retaining and expanding client relationships and delivering high-quality solutions.
The most recent analyst rating on (TBI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.
On May 14, 2025, TrueBlue, Inc. held its annual meeting of shareholders where 27,085,588 shares were represented. During the meeting, shareholders elected nine directors, approved executive compensation, amended the 2016 Omnibus Incentive Plan, and ratified Deloitte & Touche LLP as the accounting firm for the fiscal year ending December 28, 2025.
The most recent analyst rating on (TBI) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.
On May 14, 2025, TrueBlue’s Board of Directors declared a dividend of one preferred stock purchase right for each share of common stock, effective May 28, 2025. This move, part of a limited duration shareholder rights agreement, aims to protect shareholder interests against an unsolicited acquisition proposal from HireQuest, Inc. The agreement is designed to prevent any entity from gaining control of TrueBlue without paying a control premium or allowing the Board to make informed decisions, thus safeguarding the company’s and shareholders’ best interests.
The most recent analyst rating on (TBI) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.